These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 33011303)

  • 21. Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy.
    Faverio P; Bonaiti G; Bini F; Vaghi A; Pesci A
    Ther Clin Risk Manag; 2018; 14():2385-2396. PubMed ID: 30573961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Current treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)].
    Moosig F; Holle J
    Z Rheumatol; 2019 May; 78(4):333-338. PubMed ID: 30627842
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Omalizumab and Churg-Strauss syndrome.
    Giavina-Bianchi P; Giavina-Bianchi M; Agondi R; Kalil J
    J Allergy Clin Immunol; 2008 Jul; 122(1):217; author reply 217-8. PubMed ID: 18602576
    [No Abstract]   [Full Text] [Related]  

  • 24. The importance of being not significant: Blood eosinophils and clinical responses do not correlate in severe asthma patients treated with mepolizumab in real life.
    Bagnasco D; Massolo A; Bonavia M; Brussino L; Bucca C; Caminati M; Canonica GW; Caruso C; D'Amato M; De Ferrari L; Guida G; Heffler E; Lombardi C; Menzella F; Milanese M; Paoletti G; Riccio AM; Rolla G; Senna G; Testino E; Passalacqua G
    Allergy; 2020 Jun; 75(6):1460-1463. PubMed ID: 31773742
    [No Abstract]   [Full Text] [Related]  

  • 25. Development of Churg-Strauss syndrome with controlled asthma during omalizumab treatment.
    Ruppert AM; Averous G; Stanciu D; Deroide N; Riehm S; Poindron V; Pauli G; Debry C; de Blay F
    J Allergy Clin Immunol; 2008 Jan; 121(1):253-4. PubMed ID: 18206510
    [No Abstract]   [Full Text] [Related]  

  • 26. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome.
    Kim S; Marigowda G; Oren E; Israel E; Wechsler ME
    J Allergy Clin Immunol; 2010 Jun; 125(6):1336-43. PubMed ID: 20513524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Three months' administration of anti-IgE to a patient with Churg-Strauss syndrome.
    Giavina-Bianchi P; Giavina-Bianchi M; Agondi R; Kalil J
    J Allergy Clin Immunol; 2007 May; 119(5):1279; author reply 1279-80. PubMed ID: 17349685
    [No Abstract]   [Full Text] [Related]  

  • 28. Secondary loss of response to mepolizumab in severe eosinophilic asthma.
    Cormier M; Chaboillez S; Lemiere C
    J Allergy Clin Immunol Pract; 2020 Feb; 8(2):736-738. PubMed ID: 31421278
    [No Abstract]   [Full Text] [Related]  

  • 29. Updates for the treatment of EGPA.
    Raffray L; Guillevin L
    Presse Med; 2020 Oct; 49(3):104036. PubMed ID: 32652104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. One year administration of anti-IgE to a patient with Churg-Strauss syndrome.
    Giavina-Bianchi P; Agondi R; Kalil J
    Int Arch Allergy Immunol; 2008; 146(2):176. PubMed ID: 18204287
    [No Abstract]   [Full Text] [Related]  

  • 31. Eosinophil-derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma.
    Howarth P; Quirce S; Papi A; Israel E; Mallett S; Bates S; Yancey S; Albers FC; Kwon N
    Allergy; 2020 Aug; 75(8):2085-2088. PubMed ID: 32147844
    [No Abstract]   [Full Text] [Related]  

  • 32. Omalizumab treatment associated with Churg-Strauss vasculitis.
    Bargagli E; Rottoli P
    Int Arch Allergy Immunol; 2008; 145(3):268. PubMed ID: 17921677
    [No Abstract]   [Full Text] [Related]  

  • 33. Mepolizumab and eosinophil-mediated disease.
    Walsh GM
    Curr Med Chem; 2009; 16(36):4774-8. PubMed ID: 19929788
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update on immunogenicity in severe asthma: Experience with mepolizumab.
    Ortega HG; Meyer E; Brusselle G; Asano K; Prazma CM; Albers FC; Mallett SA; Yancey SW; Gleich GJ
    J Allergy Clin Immunol Pract; 2019; 7(7):2469-2475.e1. PubMed ID: 30954640
    [No Abstract]   [Full Text] [Related]  

  • 35. Familial Eosinophilic Granulomatosis with Polyangiitis in a Sister and Brother.
    Ueki Y; Oshikata C; Asai Y; Kaneko T; Tsurikisawa N
    Intern Med; 2020 Apr; 59(7):991-995. PubMed ID: 31813915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leukotriene receptor antagonists and Churg-Strauss syndrome: cause, trigger or merely an association?
    Keogh KA
    Drug Saf; 2007; 30(10):837-43. PubMed ID: 17867722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Churg-Strauss vasculitis in a patient treated with omalizumab.
    Bargagli E; Madioni C; Olivieri C; Penza F; Rottoli P
    J Asthma; 2008 Mar; 45(2):115-6. PubMed ID: 18350402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proportion of Severe Asthma Patients Eligible for Mepolizumab Therapy by Age and Age of Onset of Asthma.
    Comberiati P; McCormack K; Malka-Rais J; Spahn JD
    J Allergy Clin Immunol Pract; 2019; 7(8):2689-2696.e2. PubMed ID: 31201938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Zafirlukast and Churg-Strauss syndrome.
    Honsinger RW
    JAMA; 1998 Jun; 279(24):1949; author reply 1950. PubMed ID: 9643849
    [No Abstract]   [Full Text] [Related]  

  • 40. Zafirlukast and Churg-Strauss syndrome.
    Churg J; Churg A
    JAMA; 1998 Jun; 279(24):1949-50. PubMed ID: 9643850
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.